×
AllNewsImagesVideos Maps Shopping Books
Search tools
Did you mean: BioLineRX

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

PR Newswire
Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.;...
1 month ago

BioLineRx doses first subject in Phase II pancreatic cancer trial

Clinical Trials Arena
BioLineRx has dosed the first subject in the Phase II trial evaluating motixafortide for the treatment of first-line pancreatic cancer.
2 months ago

BioLineRx Enhances Multiple Myeloma Treatment - TipRanks.com

Tipranks
Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd. has announced a poster presentation on their product, APHEXDA (motixafortide),...
2 weeks ago

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Simply Wall Street
BioLineRx. BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases...
1 month ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Yahoo Finance
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and...
1 month ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges (NASDAQ:BLRX)

Seeking Alpha
BioLineRx's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients.
5 months ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of ...

Morningstar
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
1 month ago

HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To Know

markets.businessinsider.com
HC Wainwright & Co. has decided to maintain its Buy rating of BioLine Rx (NASDAQ:BLRX) and raise its price target from $19.00 to $21.00.
7 months ago

FDA Action Alert: BMS, Outlook and BiolineRx

BioSpace
BioLineRx Proposes Aphexda for Stem Cell Mobilization. Next week, on or before Sept. 9, the FDA will decide on BioLineRx's NDA proposing Aphexda...
8 months ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ ...

PR Newswire
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in...
2 months ago